WallStSmart

Merck & Company Inc (MRK)vsWORK Medical Technology Group LTD Ordinary Shares (WOK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 667684% more annual revenue ($65.77B vs $9.85M). MRK leads profitability with a 13.6% profit margin vs -10.9%. MRK earns a higher WallStSmart Score of 50/100 (D+).

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.30

WOK

Avoid

35

out of 100

Grade: F

Growth: 2.0Profit: 2.0Value: 5.0Quality: 6.5
Piotroski: 4/9Altman Z: 1.82
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-49.3%)

Margin of Safety

-49.3%

Fair Value

$80.88

Current Price

$120.79

$39.91 premium

UndervaluedFair: $80.88Overvalued

Intrinsic value data unavailable for WOK.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$285.64B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

WOK1 strengths · Avg: 10.0/10
Price/BookValuation
0.0x10/10

Reasonable price relative to book value

Areas to Watch

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

WOK4 concerns · Avg: 2.8/10
Altman Z-ScoreHealth
1.824/10

Grey zone — moderate risk

Market CapQuality
$118,5803/10

Smaller company, higher risk/reward

Return on EquityProfitability
-5.8%2/10

ROE of -5.8% — below average capital efficiency

Revenue GrowthGrowth
-14.4%2/10

Revenue declined 14.4%

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : WOK

The strongest argument for WOK centers on Price/Book.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Bear Case : WOK

The primary concerns for WOK are Altman Z-Score, Market Cap, Return on Equity.

Key Dynamics to Monitor

MRK profiles as a value stock while WOK is a turnaround play — different risk/reward profiles.

MRK is growing revenue faster at 4.9% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MRK scores higher overall (50/100 vs 35/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

WORK Medical Technology Group LTD Ordinary Shares

HEALTHCARE · MEDICAL DEVICES · USA

WORK Medical Technology Group Ltd is a prominent player in the medical technology sector, focusing on the research, development, and commercialization of innovative healthcare solutions. With a strong emphasis on advanced medical devices, the company strives to improve patient outcomes and tackle significant challenges in global healthcare. Its dedication to quality, innovation, and a diverse product portfolio not only enhances its market position but also aligns with the interests of institutional investors seeking opportunities in transformative healthcare advancements. As the demand for effective medical technologies continues to rise, WORK is well-positioned for sustained growth and value creation.

Visit Website →

Want to dig deeper into these stocks?